Sung Hwan Kim

Sung Hwan Kim

Auto-generated profile, based on publicly available information

Sung Hwan Kim

Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Medicine
Verified
Journal Article
Open access
PDF file
TYTae Won Yang
Tae Won Yang
HPHyun Oh Park
Hyun Oh Park
HJHa Nee Jang
Ha Nee Jang
JYJun Ho Yang
Jun Ho Yang
SKSung Hwan Kim
Sung Hwan Kim
DKDong Hun Kang
Dong Hun Kang
Patients with drug-susceptible tuberculosis (TB) show good tolerance of the medications used and have few side effects. However, medications used to treat multidrug-resistant tuberculosis (MDR-TB) have many known side effects. Here, we studied the occurrence of side effects due to treatment of patients with MDR-TB. We conducted a retrospective and consecutive review of the medical records of 256 patients who received treatment for MDR-TB between January 2006 and December 2011. One or more side effects were observed in 95 (37.1%) of the 256 patients. These side effects led to the suspension of the use of 1 or more drugs from the regimen of individualized treatment prescribed for 44 of the patients (17.2%). The side effects observed most frequently included gastrointestinal disturbance (18.4%), psychiatric disorder (5.5%), arthralgia (4.7%), hepatitis (3.9%), peripheral neuropathy (3.1%), hypothyroidism (2.3%), epileptic seizures (2%), dermatological effects (2%), ototoxicity (1.6%), and nephrotoxicity (1.2%). The treatment was successful in 220 (85.9%) patients with MDR-TB. Our study may help in formulating strategies for the timely and aggressive management of drug side effects. This may reduce the suspension of therapy and increase the rate of clinical success.

1 July 2017 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
AAAkhtar Ali
Akhtar Ali
SKSung Hwan Kim
Sung Hwan Kim
MKMin Jun Kim
Min Jun Kim
MCMee Young Choi
Mee Young Choi
SKSang Soo Kang
Sang Soo Kang
WCWan Sung Choi
Wan Sung Choi
C-X-C chemokine receptor 4 (CXCR4) stimulates cancer metastasis. NF-κB regulates CXCR4 expression in cancer cells, and O-GlcNAc modification of NF-κB promotes its transcriptional activity. Here, we determined whether CXCR4 expression is affected by O-GlcNAcylation of NF-κB in lung metastasis of cervical cancer. We found elevated levels of O-linked-N-actylglucosamine transferase (OGT) and O-GlcNAcylation in cervical cancer cells compared to those in non-malignant epithelial cells and detected increased expression of NF-κB p65 (p65) and CXCR4 in cervical cancer cells. Knockdown of OGT inhibited the O-GlcNAcylation of p65 and decreased CXCR4 expression levels in HeLa cells. Thiamet G treatment increased O-GlcNAcylated p65, which subsequently enhanced CXCR4 expression levels. Inhibition of O-GlcNAcylation by 6-Diazo-5-oxo-L-norleucine (DON) treatment decreased p65 activation, eventually inhibiting CXCR4 expression in HeLa cells. Lung tissues from mice engrafted with OGT-knockdown HeLa cells (shOGT) exhibited lower expression of Ki-67 and HPV E6 and E7 oncogenes compared to lung tissues from mice engrafted with control HeLa cells (shCTL). In addition, lung tissues from mice engrafted with shOGT cells exhibited lower p65 and CXCR4 immunoreactivity compared to tissues from mice engrafted with shCTL cells. Taken together, our data suggest that p65 O-GlcNAcylation promotes lung metastasis of cervical cancer cells by activating CXCR4 expression.

1 January 2016 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
HPHyun Oh Park
Hyun Oh Park
SKSung Hwan Kim
Sung Hwan Kim
SMSeong Ho Moon
Seong Ho Moon
JBJoung Hun Byun
Joung Hun Byun
JKJong Woo Kim
Jong Woo Kim
JYJun Ho Yang
Jun Ho Yang
Park HO, et al. Infect Chemother. 2016 Dec;48(4):317-323. https://doi.org/10.3947/ic.2016.48.4.317

8 October 2018 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YLYun Hee Lee
Yun Hee Lee
KKKi Mun Kang
Ki Mun Kang
HCHoon‐Sik Choi
Hoon‐Sik Choi
IHIn Bong Ha
In Bong Ha
HJHojin Jeong
Hojin Jeong
BJBae Kwon Jeong
Bae Kwon Jeong
Background: We compared the treatment outcomes of stereotactic body radiotherapy (SBRT) and metastasectomy in patients with pulmonary metastases.Methods: Twenty‐one patients received SBRT (total radiation doses 60 Gy in 3 fractions or 48 Gy in 4 fractions) and 30 underwent metastasectomy, most (93.3%) with wedge resection. The patients were followed for a median of 13.7 months. The tumor size in the SBRT group was larger than in the metastasectomy group (median 2.5 vs. 1.25 cm; P = 0.015). Patients with synchronous metastases were more likely to be treated with SBRT than with metastasectomy (P = 0.006).Results: There was no significant difference in the local control rates of the treatment groups (P = 0.163). Progression‐free survival (PFS) was longer in the metastasectomy than in the SBRT group (P = 0.02), with one and two‐year PFS rates of 51.1% and 46% versus 23.8% and 11.9%, respectively. The one and two‐year overall survival (OS) rates were 95% and 81.8% in the metastasectomy group and 79.5% and 68.2%, in the SBRT group, respectively. In multivariate analysis, synchronous metastasis was related to poor PFS, and tumor size was the most significant factor affecting OS. There were no significant differences in PFS and OS between treatment groups after dividing patients according to the presence or absence of synchronous metastases.Conclusions: SBRT is considered a suitable local modality against pulmonary metastases; however, patients with synchronous metastases are only likely to obtain a small benefit from local treatment with either SBRT or surgery.

1 October 2017 in Medicine
Verified
Journal Article
Open access
SMSeong Ho Moon
Seong Ho Moon
JKJong Woo Kim
Jong Woo Kim
JBJoung Hun Byun
Joung Hun Byun
SKSung Hwan Kim
Sung Hwan Kim
JCJun Young Choi
Jun Young Choi
HPHyun Oh Park
Hyun Oh Park
Several scoring systems are commonly used to evaluate severity in patients with traumatic injuries. However, there is no generally accepted standard scoring system to assess the severity of thoracic trauma, specifically in patients who have sustained severe injuries. The present study aimed to evaluate the validity of the trauma and injury severity score (TRISS) and the thorax trauma severity score (TTSS) as predictors of in-hospital mortality in patients with severe thoracic trauma. We conducted a retrospective, consecutive review of the medical records of patients with severe thoracic trauma who were managed at our institution between January 2005 and December 2015. Inclusion criteria were patients with severe thoracic injury (injury severity score > 18) who required intensive care therapy and who had no local or systemic infection. We analyzed the association between the trauma severity scores (TTSS and TRISS) and in-hospital mortality in these patients. We also determined the predictive value of the scores using receiver-operating characteristic (ROC) curves. A total of 228 patients with severe thoracic trauma were included in this study. The in-hospital mortality rate was 21.9%. There was a statistically significant association between the TRISS and in-hospital mortality (P < .001), but the association between the TTSS and in-hospital mortality was not statistically significant (P = .547). The ROC curve demonstrated adequate discrimination, as demonstrated by an area under the curve value of 0.787 for the TRISS. At a cut-off value of 25.9%, the TRISS had a sensitivity of 83.6% and specificity of 73.5% to predict in-hospital mortality. The present study demonstrated that the TRISS, but not the TTSS, can be used to predict in-hospital mortality in patients with severe thoracic trauma; hence, additional prospective studies are required.

5 October 2017 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
HPHyun Oh Park
Hyun Oh Park
DKDong Hoon Kang
Dong Hoon Kang
SMSeong Ho Moon
Seong Ho Moon
JYJun Ho Yang
Jun Ho Yang
SKSung Hwan Kim
Sung Hwan Kim
JBJoung Hun Byun
Joung Hun Byun
Hyun Oh Park, M.D., Dong Hoon Kang M.D., Seong Ho Moon, M.D., Jun Ho Yang, M.D., Sung Hwan Kim, M.D., Joung Hun Byun, M.D.. Korean J Thorac Cardiovasc Surg 2017;50:346-54. https://doi.org/10.5090/kjtcs.2017.50.5.346